SIRT6 and prostate cancer: The SIRT6 interfering efficiency in subcutaneous tumor model was confirmed by immunohistochemistry (Figure 7E) and the Ki67 staining of tumor tissues showed that the engineered exosomes suppressed the prostate cancer cell proliferation (Figure 7F).